Cytovation granted EU patent for its lead product, CyPep-1, for the treatment of cutaneous warts

Bergen, Norway – July 2016 – Cytovation, focused on the treatment of dermatological diseases, announced that it has been granted a patent across Europe for the use of its lead product, CyPep-1.

CyPep-1 has already been granted patents covering its use in the USA, China and Japan. CyPep-1 is currently in pre-clinical development for the treatment of cutaneous warts caused by human papilloma virus (HPV) and has applications in other dermatological diseases. CyPep-1 is a first-in- class peptide consisting of 27 amino acids with a unique mechanism that rapidly and selectively targets wart cells infected with human papilloma virus due to a negative charge on their cell membranes not found on healthy cells.

Kjell-inge Arnevig, CEO of Cytovation, commented: “We are delighted to have received this additional patent protection for the use of CyPep-1 in Europe. CyPep-1 has applications in multiple dermatological diseases and is poised to enter toxicology studies later this year for the treatment of cutaneous warts. ”